Literature DB >> 32364251

Alarm interventions for nocturnal enuresis in children.

Patrina Hy Caldwell1,2, Miriam Codarini3, Fiona Stewart4, Deirdre Hahn2, Premala Sureshkumar5.   

Abstract

BACKGROUND: Enuresis (bedwetting) affects up to 20% of five-year-olds and can have considerable social, emotional and psychological effects. Treatments include alarms (activated by urination), behavioural interventions and drugs.
OBJECTIVES: To assess the effects of enuresis alarms for treating enuresis in children. SEARCH
METHODS: We searched the Cochrane Incontinence Specialised Register, which contains trials identified from the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, MEDLINE In-Process, MEDLINE Epub Ahead of Print, ClinicalTrials.gov, WHO ICTRP, and handsearching of journals and conference proceedings (searched 25 June 2018), and reference lists of relevant articles. SELECTION CRITERIA: We included randomised or quasi-randomised trials of enuresis alarms or alarms combined with another intervention for treating nocturnal enuresis in children between 5 and 16 years old. DATA COLLECTION AND ANALYSIS: Two review authors independently assessed risk of bias and extracted data. MAIN
RESULTS: We included 74 trials (5983 children). At treatment completion, alarms may reduce the number of wet nights a week compared to control or no treatment (mean difference (MD) -2.68, 95% confidence interval (CI) -4.59 to -0.78; 4 trials, 127 children; low-quality evidence). Low-quality evidence suggests more children may achieve complete response (14 consecutive dry nights) with alarms compared to control or no treatment (RR 7.23, 95% CI 1.40 to 37.33; 18 trials, 827 children) and that more children may remain dry post-treatment (RR 9.67, 95% CI 4.74 to 19.76; 10 trials, 366 children; low-quality evidence). At treatment completion, we are uncertain whether there is any difference between alarms and placebo drugs in the number of wet nights a week (MD -0.96, 95% CI -2.32 to 0.41; 1 trial, 47 children; very low-quality evidence). Alarms may result in more children achieving complete response than with placebo drugs (RR 1.59, 95% CI 1.16 to 2.17; 2 trials, 181 children; low-quality evidence). No trials comparing alarms to placebo reported the number of children remaining dry post-treatment. Compared with control alarms, code-word alarms probably slightly increase the number of children achieving complete response at treatment completion (RR 1.11, 95% CI 0.97 to 1.27; 1 trial, 353 children; moderate-quality evidence) but there is probably little to no difference in the number of children remaining dry post-treatment (RR 0.91, 95% CI 0.79 to 1.05; moderate-quality evidence). Very low-quality evidence means we are uncertain if there are any differences in effectiveness between the other different types of alarm. At treatment completion, alarms may reduce the number of wet nights a week compared with behavioural interventions (waking, bladder training, dry-bed training, and star chart plus rewards) (MD -0.81, 95% CI -2.01 to 0.38; low-quality evidence) and may increase the number of children achieving complete response (RR 1.77, 95% CI 0.98 to 3.19; low-quality evidence) and may slightly increase the number of children remaining dry post-treatment (RR 1.39, 95% CI 0.81 to 2.41; low-quality evidence). The evidence relating to alarms compared with desmopressin in the number of wet nights a week (MD -0.64, 95% CI -1.77 to 0.49; 4 trials, 285 children) and the number of children achieving complete response at treatment completion (RR 1.12, 95% CI 0.93 to 1.36; 12 trials, 1168 children) is low-quality, spanning possible harms and possible benefits. Alarms probably slightly increase the number of children remaining dry post-treatment compared with desmopressin (RR 1.30, 95% CI 0.92 to 1.84; 5 trials, 565 children; moderate-quality evidence). At treatment completion, we are uncertain if there is any difference between alarms and tricyclics in the number of wet nights a week, the number of children achieving complete response or the number of children remaining dry post-treatment, because the quality of evidence is very low. Due to very low-quality evidence we are uncertain about any differences in effectiveness between alarms and cognitive behavioural therapy, psychotherapy, hypnotherapy and restricted diet. Alarm plus desmopressin may reduce the number of wet nights a week compared with desmopressin monotherapy (MD -0.88, 95% CI -0.38 to -1.38; 2 trials, 156 children; low-quality evidence). Alarm plus desmopressin may increase the number of children achieving complete response (RR 1.32, 95% CI 1.08 to 1.62; 5 trials, 359 children; low-quality evidence) and the number of children remaining dry post-treatment (RR 2.33, 95% CI 1.26 to 4.29; 2 trials, 161 children; low-quality evidence) compared with desmopressin alone. Alarm plus dry-bed training may increase the number of children achieving a complete response compared to dry-bed training alone (RR 3.79, 95% CI 1.85 to 7.77; 1 trial, 80 children; low-quality evidence). It is unclear if there is any difference in the number of children remaining dry post-treatment because of the wide confidence interval (RR 0.56, 95% CI 0.15 to 2.12; low-quality evidence). Due to very low-quality evidence, we are uncertain about any differences in effectiveness between alarm plus bladder training versus bladder training alone. Of the 74 included trials, 17 reported one or more adverse events, nine reported no adverse events and 48 did not mention adverse events. Adverse events attributed to alarms included failure to wake the child, ringing without urination, waking others, causing discomfort, frightening the child and being too difficult to use. Adverse events of comparator interventions included nose bleeds, headaches and abdominal pain. There is probably a slight increase in adverse events between code-word alarm and standard alarm (RR 1.34, 95% CI 0.75 to 2.38; moderate-quality evidence), although we are uncertain because of the wide confidence interval. Alarms probably reduce the number of children experiencing adverse events compared with desmopressin (RR 0.38, 95% CI 0.20 to 0.71; 5 trials, 565 children; moderate-quality evidence). Very low-quality evidence means we cannot be certain whether the adverse event rate for alarms is lower than for other treatments. AUTHORS'
CONCLUSIONS: Alarm therapy may be more effective than no treatment in reducing enuresis in children. We are uncertain if alarm therapy is more effective than desmopressin but there is probably a lower risk of adverse events with alarms than with desmopressin. Despite the large number of trials included in this review, further adequately-powered trials with robust randomisation are still needed to determine the full effect of alarm therapy.
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32364251      PMCID: PMC7197139          DOI: 10.1002/14651858.CD002911.pub3

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  156 in total

Review 1.  Drugs for nocturnal enuresis in children (other than desmopressin and tricyclics).

Authors:  Aniruddh V Deshpande; Patrina H Y Caldwell; Premala Sureshkumar
Journal:  Cochrane Database Syst Rev       Date:  2012-12-12

2.  Behavioral and self-concept changes after six months of enuresis treatment: a randomized, controlled trial.

Authors:  S Longstaffe; M E Moffatt; J C Whalen
Journal:  Pediatrics       Date:  2000-04       Impact factor: 7.124

3.  Dry-bed training: rapid elimination of childhood enuresis.

Authors:  N H Azrin; T J Sneed; R M Foxx
Journal:  Behav Res Ther       Date:  1974-09

Review 4.  The efficacy of alarm therapy versus desmopressin therapy in the treatment of primary mono-symptomatic nocturnal enuresis: a systematic review.

Authors:  Nina Perrin; Lynn Sayer; Alison While
Journal:  Prim Health Care Res Dev       Date:  2013-11-19       Impact factor: 1.458

5.  Primary enuresis: relative success of three methods of treatment.

Authors:  J B McKendry; D A Stewart; F Khanna; C Netley
Journal:  Can Med Assoc J       Date:  1975-11-22       Impact factor: 8.262

6.  Effect of 1-deamino 8-D-arginine vasopressin spray on nasal cytology and mucociliary clearance in patients with nocturnal enuresis.

Authors:  Ertap Akoğlu; Sadik Görür; Esin Atik; Semsettin Okuyucu; Ozlem Sangün
Journal:  Int J Pediatr Otorhinolaryngol       Date:  2006-08-09       Impact factor: 1.675

7.  Factors influencing quality of life in children with urinary incontinence.

Authors:  Aniruddh V Deshpande; Jonathan C Craig; Grahame H H Smith; Patrina H Y Caldwell
Journal:  J Urol       Date:  2011-07-23       Impact factor: 7.450

Review 8.  Psychosocial implications of nocturnal enuresis.

Authors:  W J Warzak
Journal:  Clin Pediatr (Phila)       Date:  1993-07       Impact factor: 1.168

9.  Assignment of dominant inherited nocturnal enuresis (ENUR1) to chromosome 13q.

Authors:  H Eiberg; I Berendt; J Mohr
Journal:  Nat Genet       Date:  1995-07       Impact factor: 38.330

10.  [A randomized controlled clinical trial for treatment of children with primary nocturnal enuresis].

Authors:  Jun Ma; Yi-wen Zhang; Hong Wu; Fan Jiang; Xing-ming Jin
Journal:  Zhonghua Er Ke Za Zhi       Date:  2007-03
View more
  3 in total

1.  High success rate of nocturnal enuresis treatment during the stay-home period for COVID-19.

Authors:  Takahisa Kimiya; Masayoshi Shinjoh; Hiroshi Asanuma; Tomohiro Inoguchi; Takao Takahashi
Journal:  Int J Urol       Date:  2022-03-03       Impact factor: 2.896

2.  Impact of New vs. Old International Children's Continence Society Standardization on the Classification of Treatment Naïve Enuresis Children at Screening: The Value of Voiding Diaries and Questionnaires.

Authors:  Sevasti Karamaria; Nadejda Ranguelov; Pernille Hansen; Veerle De Boe; Pieter Verleyen; Nathalie Segers; Johan Vande Walle; Lien Dossche; An Bael
Journal:  Front Pediatr       Date:  2022-03-28       Impact factor: 3.418

Review 3.  Bibliometric and visual analysis of nocturnal enuresis from 1982 to 2022.

Authors:  Wenjie Li; Guang Yang; Wenxiu Tian; Yunqi Li; Lei Zhang; Youjie Wang; Yanlong Hong
Journal:  Front Pediatr       Date:  2022-08-12       Impact factor: 3.569

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.